Competing interests
JPM has declared the following competing interests: Kite, Novartis, Bristol Myers Squibb, Allovir, Nektar, Sana, CRISPR (Ad Boards and consulting). LM has declared the following competing interests: Incyte (promotional speaker). LP has no competing interests. ML has declared the following competing interests: clinical trial finding (Abbvie, Amgen, Astellas, Novartis, Syndax, Actinium, Pluri-Biotech); advisory board (Jazz Pharmaceuticals); data monitoring board (BioSight). SDR has declared the following competing interests: SIRPant Immunotherapeutics (community advisory board), Realta Life Sciences (consultant). BA has no competing financial interests. RT has no competing financial interests. HML has declared the following competing interests: Actinium pharmaceuticals, Inc (consultant); Partner Therapeutics (consultant and stock options); Jazz Pharmaceuticals (speaker bureau and consultant); Pluri-Biotech, Inc.(consultant); Bristol-Myers Squibb (data safety monitoring board); Seattle Genetics (consultant and promotional speaker); AstraZeneca (promotional speaker); BioSight (data safety monitoring board); CSL Behring (consultant). JMR has declared the following competing interests: BioSight (consultant); Pluri-Biotech, Inc. (consultant). TZ has received honoraria from AbbVie, Orgenesis Inc, BioSight Ltd, Cellect Biotechnology, Janssen, Novartis and Gilead Sciences for participating in an advisory board or speaker’s bureau. MS, DR and NH are current employees of Pluri-Biotech.